Christopher Sechler - John Hancock Secretary, Chief Legal Officer
| BTO Fund | USD 38.23 0.51 1.35% |
Mr. Christopher Sechler is Secretary, Chief Legal Officer of John Hancock Financial Opportunities Fund. He is Vice President and Deputy Chief Counsel, John Hancock Investments Assistant Vice President and Senior Counsel, John Hancock Investments Chief Legal Officer and Secretary, John Hancock retail funds, John Hancock Funds II, John Hancock Variable Insurance Trust, John Hancock Collateral Trust and John Hancock ExchangeTraded Fund Trust Assistant Secretary of John Hancock Advisers, LLC and John Hancock Investment Management Services, LLC .
| Age | 47 |
| Tenure | 6 years |
| Phone | 617-663-2430 |
| Web | https://www.jhfunds.com/Fund/Overview.aspx?ProductType=ClosedEnd&FundID=GC09&ClassCode=CE&BackToFundTableType=Price |
John Hancock Management Performance (%)
The company has Return on Asset of 0.9 % which means that on every $100 spent on assets, it made $0.9 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (7.97) %, meaning that it generated no profit with money invested by stockholders. John Hancock's management efficiency ratios could be used to measure how well John Hancock manages its routine affairs as well as how well it operates its assets and liabilities.Similar Money Managers
| Showing other executives | One Year Return | ||
| Elizabeth Nabel | Tekla Healthcare Investors | 67 | |
| Lucinda Stebbins | Tekla Healthcare Investors | 73 | |
| Albert Laskaj | Cohen And Steers | 43 | |
| Laurie Lodolo | Flaherty and Crumrine | 56 | |
| William Reardon | Tekla Life Sciences | 74 | |
| Rakesh Jain | Tekla Healthcare Opportunities | 69 | |
| William Reardon | Tekla Healthcare Investors | 74 | |
| Michael Castellano | BlackRock Science Tech | 75 | |
| Laura Woodward | Tekla World Healthcare | 51 | |
| Lucinda Stebbins | Tekla Healthcare Opportunities | 73 | |
| Lisa Phelan | Cohen Steers Qualityome | 52 | |
| Dr MS | Tekla Healthcare Investors | 71 | |
| Mary Anstine | Reaves Utility If | 79 | |
| Lisa Curcio | Royce Value Closed | 60 | |
| Laura Woodward | Tekla Healthcare Investors | 51 | |
| Peter Hoglund | Royce Value Closed | 54 | |
| Peter Branner | Tekla Life Sciences | 60 | |
| John Denneen | Royce Value Closed | 53 | |
| William Reardon | Tekla World Healthcare | 74 | |
| Laura Woodward | Tekla Healthcare Opportunities | 51 | |
| Frank Gentile | Tekla Healthcare Investors | 62 | |
Management Performance
| Return On Equity | -7.97 | |||
| Return On Asset | 0.9 |
John Hancock Financial Leadership Team
Elected by the shareholders, the John Hancock's board of directors comprises two types of representatives: John Hancock inside directors who are chosen from within the company, and outside directors, selected externally and held independent of John. The board's role is to monitor John Hancock's management team and ensure that shareholders' interests are well served. John Hancock's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, John Hancock's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Warren Thomson, Non-Independent Trustee | ||
| Gregory Russo, Independent Trustee | ||
| Frances Rathke, Independent Trustee | ||
| Christopher Sechler, Secretary, Chief Legal Officer | ||
| William Cunningham, Independent Trustee | ||
| James Oates, Independent Chairman of the Board of Trustees | ||
| James Boyle, Non Independent Trustee | ||
| Deborah Jackson, Independent Trustee | ||
| Marianne Harrison, Trustee | ||
| Peter Burgess, Independent Trustee | ||
| Charles Bardelis, Independent Trustee | ||
| Francis Knox, Chief Compliance Officer | ||
| Steven Pruchansky, Independent Vice Chairman of the Board of Trustees | ||
| Theron Hoffman, Independent Trustee | ||
| Charles Rizzo, Chief Financial Officer | ||
| Grace Fey, Independent Trustee | ||
| Andrew Arnott, Executive Vice President | ||
| Hassell McClellan, Independent Chairman of the Board of Trustees | ||
| Trevor Swanberg, Chief Compliance Officer | ||
| Salvatore Schiavone, Treasurer |
John Fund Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right fund is not an easy task. Is John Hancock a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.97 | |||
| Return On Asset | 0.9 | |||
| Profit Margin | (238.16) % | |||
| Operating Margin | 51.42 % | |||
| Current Valuation | 808.68 M | |||
| Shares Outstanding | 19.17 M | |||
| Shares Owned By Insiders | 0.04 % | |||
| Shares Owned By Institutions | 20.80 % | |||
| Number Of Shares Shorted | 12.55 K | |||
| Price To Earning | 2.71 X |
Pair Trading with John Hancock
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if John Hancock position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in John Hancock will appreciate offsetting losses from the drop in the long position's value.Moving together with John Fund
Moving against John Fund
| 0.86 | KO | Coca Cola Aggressive Push | PairCorr |
| 0.86 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.83 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.78 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.68 | BA | Boeing Fiscal Year End 29th of January 2025 | PairCorr |
The ability to find closely correlated positions to John Hancock could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace John Hancock when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back John Hancock - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling John Hancock Financial to buy it.
The correlation of John Hancock is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as John Hancock moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if John Hancock Financial moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for John Hancock can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in John Fund
John Hancock financial ratios help investors to determine whether John Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in John with respect to the benefits of owning John Hancock security.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |